Related Experiment Video

Updated: Jul 23, 2025

Removal and Replacement of Endogenous Ligands from Lipid-Bound Proteins and Allergens
09:09

Removal and Replacement of Endogenous Ligands from Lipid-Bound Proteins and Allergens

Published on: February 24, 2021

3.0K

Alectinib-induced rash unresponsive to desensitization: a case report and literature review

Robin Raquel Rodriguez1, Jessie Dindak2, Janet Kline2

  • 1Department of Medical Oncology, Allegheny Health Network, Pittsburgh, PA, USA. robinraquel@yahoo.com.

BMC Pulmonary Medicine
|July 15, 2023
PubMed
Abstract

Insights

A rare, severe rash occurred in a patient treated with Alectinib for non-small cell lung cancer (NSCLC). Desensitization attempts were unsuccessful, highlighting challenges in managing targeted therapy side effects.

Area of Science:

  • Oncology
  • Pharmacology
  • Dermatology

Background:

  • Targeted therapies offer new hope for non-small cell lung cancer (NSCLC) patients with specific mutations.
  • Understanding and managing side effects of these novel treatments, like Alectinib, is crucial for providers.
  • Alectinib is a second-generation tyrosine kinase inhibitor for ALK-mutated NSCLC.

Conclusions:

  • Rare side effects, such as severe rash, can occur with Alectinib treatment in NSCLC.
  • This case highlights the challenges in managing Alectinib-induced adverse events.
  • Reporting such cases aids in developing future strategies for preventing, treating, and rechallenging patients on targeted therapies.
Keywords:
ALK gene mutationNon-small cell lung cancerRashTargeted therapy

More Related Videos

Granulocyte-dependent Autoantibody-induced Skin Blistering12:23

Granulocyte-dependent Autoantibody-induced Skin Blistering

Published on: October 12, 2012

10.6K
Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment06:47

Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment

Published on: September 27, 2017

9.7K

Related Concept Videos

Allergic Drug Reactions01:27

Allergic Drug Reactions

Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
895
Allergic Reactions02:06

Allergic Reactions

Overview
27.8K
Desensitization and Tachyphylaxis01:20

Desensitization and Tachyphylaxis

Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
1.8K
Physical Properties of Amines01:26

Physical Properties of Amines

Amines with low molecular weight are usually gaseous at room temperature, while those with high molecular weight are liquid or solids in nature. Usually, low molecular weight amines have a rotten fish-like smell. Diamines typically have a pungent smell. For instance, cadaverine and putrescine, depicted in Figure 1, are two molecules responsible for decaying tissue.
3.2K
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
368
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
204